Richmond Hill, Ontario – January 20, 2012 – Qvella Corporation is pleased to announce that it has secured financing from a syndicate of investors led by HTX totaling $2.5M. “This infusion of capital will support the development of our whole blood sample prep and bacterial ID system and will get us closer to realizing our goal of having a fully automated platform for the detection and identification of bacterial infections from un-enriched samples”, said Dr. Tino Alavie, President of Qvella, “We are grateful to HTX and all our supporters in helping us bring our technology one step closer to commercial reality. The advent of rapid molecular and personalized diagnostics will redefine the detection and treatment of infectious disease.”